NEW YORK, Feb 5, 2026, 18:54 ET — After-hours
- After hours, Confluent shares hovered near $30.36, slightly below IBM’s $31 per share cash bid
- A fresh SEC filing included extra merger disclosures amid rising shareholder demands and ongoing lawsuits
- The next key trigger for investors is the shareholder vote set for Feb. 12
Confluent shares barely moved in after-hours trading Thursday. The data-software firm submitted fresh merger disclosures as it prepares for a shareholder vote on its planned IBM acquisition.
This filing matters because the stock is behaving more like a merger play than a growth stock. With the vote just days away, any legal hitches or extra filings could delay the closing—or at least raise questions about when it will happen.
Confluent closed the regular session around $30.34 and hovered near $30.36 in after-hours trading. This puts the stock about 2% shy of IBM’s $31-per-share cash bid — a difference called the deal spread, which typically factors in both time value and the market’s view on deal completion risk.
Confluent disclosed in a Form 8-K on Wednesday that it has been hit with 17 demand letters from alleged shareholders and is facing two lawsuits in New York state court. The suits claim the merger proxy statement omitted material information. While Confluent maintains its disclosures were legally compliant, the company opted to provide supplemental disclosures to lower litigation risks and associated expenses.
In December, IBM struck a deal to acquire Confluent for $31 a share in cash, pegging the enterprise value at $11 billion, the companies announced. IBM CEO Arvind Krishna touted the move as a step toward building a “smart data platform” for enterprise IT. Confluent’s CEO Jay Kreps expressed excitement about joining IBM and leveraging its scale to speed up their strategy. IBM Newsroom
Confluent provides software that enables real-time data movement between systems, acting as a crucial plumbing layer beneath analytics, apps, and automated workflows. IBM is marketing the deal as a solution to link data across public and private clouds, simplifying the process of running AI applications that rely on current, reliable information.
The paperwork highlights a common late-stage risk in U.S. deals: shareholder lawsuits targeting the proxy statement, typically pushing for extra disclosures or fees. While these suits don’t always stop a deal, they can cause delays—particularly if a court is asked to halt the shareholder vote.
The main risk for investors still boils down to the standard hurdles — securing regulatory green lights across several regions, changes in IBM or Confluent’s commitment to seal the deal, or a shareholder vote that falls short despite backing agreements. Should the deal stall, expect the spread to jump sharply, with the stock reverting to trading based on Confluent’s independent prospects.
Confluent investors will vote on the transaction at the shareholder meeting set for Feb. 12. Traders are also monitoring for any new proxy supplements, updates on lawsuits, or indications that regulators might prolong reviews abroad.
Related articles: NYSE:IBM
